Literature DB >> 1116874

Pathogenecity of Yersinia enterocolitica for mice.

P B Carter.   

Abstract

A laboratory infection of Yersinia enterocolitica in mice which closely resembles the naturally acquired human infection is described Intravenous inoculation of mice with small numbers of Y. enterocolitica gives rise to a systemic, pyogenic infection involving primarily the spleen, liver, and lungs. Massive neutrophil infiltration of these organs occurs early in the infection, eventually leading to large abscesses and pulmonary consolidation. Mice infected intragastrically show neutophil infiltration in the Peyer's patches of the distal ileum less than 24h postinfection. The Peyer's patches are unable to contain the infection which spreads to the mesenteric lymph node, causing large abscesses in the medullary regions. Soon after, the infection becomes systemic with abscesses forming in the liver, spleen, and lungs, and the total peripheral leukocyte count rises dramatically to over 30,000/mm2. A serological response, in the form of agglutinating antibody, begins to appear 2 weeks after infection. Possible causes of death and the usefulness of this infectious disease model are discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1116874      PMCID: PMC415041          DOI: 10.1128/iai.11.1.164-170.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  [INVESTIGATIONS ON THE CULTURAL--BIOCHEMICAL, SEROLOGIC, EXPERIMENTAL ANIMAL AND IMMUNOLOGIC PROPERTIES OF A TYPE OF BACTERIA CALLED TEMPORARILY "PASTEURELLA X"].

Authors:  W KNAPP; E THAL
Journal:  Zentralbl Bakteriol Orig       Date:  1963-12

2.  [Pasteurella pseudotuberculosis as causative agent of mesenteric lymphadenitis in man].

Authors:  W KNAPP
Journal:  Zentralbl Bakteriol Orig       Date:  1954

Review 3.  [Human "Yersinia enterocolitica" infections in 1970, with a report of 642 recent cases. Clinical aspects and epidemiologic perspectives].

Authors:  H H Mollaret
Journal:  Pathol Biol (Paris)       Date:  1971-02

4.  [Clinic and diagnosis of enteric infections in man by Yersinia enterocolitica (author's transl)].

Authors:  W Knapp; J Lysy; C Knapp; W Stille; U Goll
Journal:  Infection       Date:  1973       Impact factor: 3.553

5.  Mesenteric lymphadenitis and terminal ileitis due to yersinia pseudotuberculosis.

Authors:  J Weber; N B Finlayson; J B Mark
Journal:  N Engl J Med       Date:  1970-07-23       Impact factor: 91.245

6.  [Contribution to the study of a new bacteria group (Yersinia enterocolitica) related to the Malassez-Vignal bacillus. II. Experimental pathogenic capacity].

Authors:  H H Mollaret; J C Guillon
Journal:  Ann Inst Pasteur (Paris)       Date:  1965-10

7.  Yersinia enterocolitica (Pasteurella x) in human enteric infections.

Authors:  S Winblad; B Niléhn; N H Sternby
Journal:  Br Med J       Date:  1966-12-03

8.  New strain of Yersinia enterocolitica pathogenic for rodents.

Authors:  P B Carter; C F Varga; E E Keet
Journal:  Appl Microbiol       Date:  1973-12

9.  Comparative immunogenicity of heat-killed and living oral Salmonella vaccines.

Authors:  F M Collins; P B Carter
Journal:  Infect Immun       Date:  1972-10       Impact factor: 3.441

10.  Experimental Yersinia enterocolitica infection in mice: kinetics of growth.

Authors:  P B Carter; F M Collins
Journal:  Infect Immun       Date:  1974-05       Impact factor: 3.441

View more
  89 in total

1.  Identification of a locus involved in systemic dissemination of Yersinia enterocolitica.

Authors:  K M Nelson; G M Young; V L Miller
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

2.  Deletion of amino acids 29 to 81 in adhesion protein YadA of Yersinia enterocolitica serotype O:8 results in selective abrogation of adherence to neutrophils.

Authors:  A Roggenkamp; K Ruckdeschel; L Leitritz; R Schmitt; J Heesemann
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

3.  YmoA negatively regulates expression of invasin from Yersinia enterocolitica.

Authors:  Damon W Ellison; Briana Young; Kristin Nelson; Virginia L Miller
Journal:  J Bacteriol       Date:  2003-12       Impact factor: 3.490

4.  Expression, purification, structural and functional analysis of SycB: a type three secretion chaperone from Yersinia enterocolitica.

Authors:  Abhishek Basu; Rakesh Chatterjee; Saumen Datta
Journal:  Protein J       Date:  2012-01       Impact factor: 2.371

5.  Involvement of M cells in the bacterial invasion of Peyer's patches: a common mechanism shared by Yersinia enterocolitica and other enteroinvasive bacteria.

Authors:  A Grützkau; C Hanski; H Hahn; E O Riecken
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

6.  Yersinia enterocolitica invasin-dependent and invasin-independent mechanisms of systemic dissemination.

Authors:  Scott A Handley; Rodney D Newberry; Virginia L Miller
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

7.  Characterization of a novel porin involved in systemic Yersinia enterocolitica infection.

Authors:  Shirly Mildiner-Earley; Virginia L Miller
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

8.  Application of comparative phylogenomics to study the evolution of Yersinia enterocolitica and to identify genetic differences relating to pathogenicity.

Authors:  Sarah L Howard; Michael W Gaunt; Jason Hinds; Adam A Witney; Richard Stabler; Brendan W Wren
Journal:  J Bacteriol       Date:  2006-05       Impact factor: 3.490

9.  The diabetic ocular environment facilitates the development of endogenous bacterial endophthalmitis.

Authors:  Phillip S Coburn; Brandt J Wiskur; Elizabeth Christy; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-01       Impact factor: 4.799

10.  Pathogenesis of defined invasion mutants of Yersinia enterocolitica in a BALB/c mouse model of infection.

Authors:  J C Pepe; M R Wachtel; E Wagar; V L Miller
Journal:  Infect Immun       Date:  1995-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.